| Dr Roderick D Ekmark, MD | |
|
101 Woodbridge Dr Bldg B, Ste 101 And 102, La Vernia, TX 78121-0109 | |
| (830) 581-8027 | |
| (830) 244-0833 |
| Full Name | Dr Roderick D Ekmark |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 101 Woodbridge Dr Bldg B, La Vernia, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063693398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | P0974 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advanced Hh, Llc | Seguin, TX | Home health agency |
| Connally Memorial Medical Center | Floresville, TX | Hospital |
| Guadalupe Regional Medical Center | Seguin, TX | Hospital |
| Entity Name | Roderick D Ekmark Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861181364 PECOS PAC ID: 9335506211 Enrollment ID: O20230608000664 |
News Archive
Researchers at the MRC Laboratory of Molecular Biology in the United Kingdom have determined the crystal structure of Parkin, a protein found in cells that when mutated can lead to a hereditary form of Parkinson's disease.
A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D.
Women taking beta-blockers for hypertension with no prior history of cardiovascular disease (CVD) have a nearly 5% higher risk for heart failure than men when they present to hospitals with acute coronary syndrome, according to new research published today in Hypertension, an American Heart Association journal.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Roderick D Ekmark, MD Po Box 1482, La Vernia, TX 78121-1422 Ph: (830) 581-8027 | Dr Roderick D Ekmark, MD 101 Woodbridge Dr Bldg B, Ste 101 And 102, La Vernia, TX 78121-0109 Ph: (830) 581-8027 |
News Archive
Researchers at the MRC Laboratory of Molecular Biology in the United Kingdom have determined the crystal structure of Parkin, a protein found in cells that when mutated can lead to a hereditary form of Parkinson's disease.
A new paper shows that human TLR3, TLR7, and TLR8 receptors are activated with naturally occurring RNA, but this is eliminated once modified nucleosides such as m5C, m6A, m5U s2U, or pseudouridine are incorporated.
JDRF-funded researchers have begun enrolling adult patients with type 1 diabetes (T1D) in the REMOVAL study, to test whether metformin-a drug commonly used to treat type 2 diabetes-could help prevent or reduce the risk of cardiovascular complications in people with T1D.
Women taking beta-blockers for hypertension with no prior history of cardiovascular disease (CVD) have a nearly 5% higher risk for heart failure than men when they present to hospitals with acute coronary syndrome, according to new research published today in Hypertension, an American Heart Association journal.
Gilead Sciences, Inc. announced today plans to launch authorized generic versions of Epclusa and Harvoni, Gilead's leading treatments for chronic hepatitis C virus, in the United States, through a newly created subsidiary, Asegua Therapeutics LLC.
› Verified 2 days ago